Michael Friedländer

924 total papers · 62.8k total citations
492 papers, 27.3k citations indexed

About

Michael Friedländer is a scholar working on Oncology, Reproductive Medicine and Genetics. According to data from OpenAlex, Michael Friedländer has authored 492 papers receiving a total of 27.3k indexed citations (citations by other indexed papers that have themselves been cited), including 273 papers in Oncology, 234 papers in Reproductive Medicine and 149 papers in Genetics. Recurrent topics in Michael Friedländer's work include Ovarian cancer diagnosis and treatment (224 papers), BRCA gene mutations in cancer (131 papers) and PARP inhibition in cancer therapy (120 papers). Michael Friedländer is often cited by papers focused on Ovarian cancer diagnosis and treatment (224 papers), BRCA gene mutations in cancer (131 papers) and PARP inhibition in cancer therapy (120 papers). Michael Friedländer collaborates with scholars based in Australia, United States and United Kingdom. Michael Friedländer's co-authors include David W. Hedley, Ian W. Taylor, Elizabeth A. Musgrove, Catherine A. Rugg, M. William Audeh, Ursula A. Matulonis, James Carmichael, Clare L. Scott, David Goldstein and Matthew C. Kiernan and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Michael Friedländer

474 papers receiving 26.7k citations

Hit Papers

Method for analysis of ce... 1983 2026 1997 2011 1983 2010 2012 2010 2014 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.
    1983 1.8k citations David W. Hedley, Michael Friedländer et al. Journal of Histochemistry & Cytochemistry profile →
  2. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    2010 1.7k citations M. William Audeh, James Carmichael et al. The Lancet profile →
  3. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
    2012 1.3k citations Jonathan A. Ledermann, Philipp Harter et al. New England Journal of Medicine profile →
  4. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
    2010 1.3k citations Andrew Tutt, Mark E. Robson et al. The Lancet profile →
  5. Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
    2014 1.2k citations Bella Kaufman, Ronnie Shapira‐Frommer et al. Journal of Clinical Oncology profile →
  6. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
    2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology profile →
  7. BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
    2012 847 citations Kathryn Alsop, Sián Fereday et al. Journal of Clinical Oncology profile →
  8. Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
    2013 555 citations Susanna B. Park, David Goldstein et al. CA A Cancer Journal for Clinicians profile →
  9. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
    2009 498 citations Michael A. Bookman, Mark F. Brady et al. Journal of Clinical Oncology profile →
  10. Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)
    2011 448 citations Ignace Vergote, Elizabeth A. Eisenhauer et al. International Journal of Gynecological Cancer profile →
  11. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
    2014 425 citations Amit M. Oza, David Cibula et al. The Lancet Oncology profile →
  12. The importance of patient-reported outcomes in clinical trials and strategies for future optimization
    2018 366 citations Rebecca Mercieca‐Bebber, Madeleine King et al. SHILAP Revista de lepidopterología profile →
  13. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
    2016 308 citations Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology profile →
  14. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
    2021 242 citations Jonathan S. Berek, Malte Renz et al. International Journal of Gynecology & Obstetrics profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Michael Friedländer 15.6k 9.8k 7.4k 5.2k 4.5k 492 27.3k
Ursula A. Matulonis 13.3k 0.9× 8.2k 0.8× 7.9k 1.1× 2.7k 0.5× 3.1k 0.7× 439 23.0k
Amit M. Oza 10.7k 0.7× 7.0k 0.7× 7.4k 1.0× 1.8k 0.3× 3.5k 0.8× 596 21.6k
Karen H. Lu 6.8k 0.4× 8.3k 0.8× 7.4k 1.0× 3.9k 0.8× 4.7k 1.0× 430 21.5k
Beth Y. Karlan 6.4k 0.4× 6.6k 0.7× 8.0k 1.1× 4.3k 0.8× 3.9k 0.8× 335 18.8k
Martin Gore 14.4k 0.9× 4.9k 0.5× 13.0k 1.7× 2.3k 0.4× 5.0k 1.1× 382 29.4k
Andrew Berchuck 5.8k 0.4× 6.9k 0.7× 8.1k 1.1× 2.9k 0.6× 3.8k 0.8× 358 19.8k
Robert L. Coleman 7.7k 0.5× 9.4k 1.0× 7.6k 1.0× 1.6k 0.3× 3.5k 0.8× 688 23.1k
Douglas A. Levine 6.7k 0.4× 7.3k 0.7× 9.2k 1.2× 2.0k 0.4× 6.2k 1.4× 256 22.3k
Steven A. Narod 14.0k 0.9× 7.0k 0.7× 12.0k 1.6× 20.0k 3.8× 12.5k 2.7× 703 41.0k
Frédéric Amant 7.2k 0.5× 8.9k 0.9× 3.7k 0.5× 1.5k 0.3× 3.2k 0.7× 553 21.8k

Countries citing papers authored by Michael Friedländer

Since Specialization
Citations

This map shows the geographic impact of Michael Friedländer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Friedländer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Friedländer more than expected).

Fields of papers citing papers by Michael Friedländer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Friedländer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Friedländer. The network helps show where Michael Friedländer may publish in the future.

Co-authorship network of co-authors of Michael Friedländer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Friedländer. A scholar is included among the top collaborators of Michael Friedländer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Friedländer. Michael Friedländer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacques Blacher Breakdown of academic impact, for papers by Roger J. Packer Breakdown of academic impact, for papers by Kenneth M. Kent Breakdown of academic impact, for papers by Hongtao Yu Breakdown of academic impact, for papers by David Menon Breakdown of academic impact, for papers by Rodolphe Clérac Breakdown of academic impact, for papers by Joost N. H. Reek Breakdown of academic impact, for papers by Alex van Belkum
Rankless by CCL
2026